Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05434156Phase 1Active Not Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Role: lead

NCT05674669Phase 1Completed

A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers

Role: lead

NCT04421105Phase 1Completed

A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years

Role: lead

All 3 trials loaded